Skip to main content
. 2022 Mar 19;25:78–97. doi: 10.1016/j.omto.2022.03.008

Table 1.

Examples of pre-clinical studies on the use of MSC-OV

Oncolytic virus Cancer type Results Reference
MSCs as a carrier of systemically delivered OVs
MV-CEA ovarian cancer
  • -

    protection of oMV from antibody neutralization

 Mader et al.55
  • -

    localization of MSC to peritoneal tumors

  • -

    enhancement of survival of measles-immune tumor-bearing mice

G47Δ-based recombinant oHSV melanoma brain-metastaticcancer
  • -

    migration to the tumor site in the brain

 Du et al.95
  • -

    increased anti-tumor immune response when combined with PD-L1 blockade

D24RGD ovarian cancer
  • -

    increased targeted delivery efficiency

 Dembinski et al.96
  • -

    reduced systemic toxicity

HCC-oAd hepatocellular carcinoma
  • -

    homing to HCC tumors

 Yoon et al.15
  • -

    cancer-specific killing effects through active viral replication within MSCs

  • -

    reduction of overall toxicity

ICOVIR-5 lung adenocarcinoma
  • -

    reduction of tumor growth and systemic activation of innate and adaptive immune response by MSCs (syngeneic or allogeneic) carrying the virus

 Morales-Molina et al.97
  • -

    increased infiltration of leukocytes into the core of the tumor

oAd d1E102 renal adenocarcinoma, melanoma
  • -

    reduction of tumor volumes

 Morales-Molina et al.98
  • -

    increased tumor immune infiltration by tumor-associated macrophages, NK cells, and tumor-infiltrating lymphocytes

Ad5/3 ovarian carcinoma
  • -

    increased survival

 Komarova et al.99
  • -

    decreased tumor burden

CRAdNTR colorectal cancer
  • -

    protection of oAd from neutralization

 Ho et al.100
  • -

    oncolysis and tumor growth inhibition

  • -

    MSC-mediated activation of co-administered pro-drug (CB1954)

vMyxgfp glioblastoma multiforme
  • -

    reduction of brain tumor size

 Josiah et al.38
  • -

    increased survival

Immunotherapy applications of MSC-OVs
ICOVIR-5 + CSF osteosarcoma
  • -

    reduced tumor growth

 Morales-Molina et al.101
  • -

    higher tumor immune infiltration

  • -

    reduced T cell exhaustion

oAd ICOVIR-15 + PBMC lung adenocarcinoma
  • -

    increased anti-tumor efficacy

 Moreno et al.102
oMyx + IL-15 (vMyx-IL15Rα-tdTr) pulmonary melanoma
  • -

    reduction in the number of pulmonary foci

 Jazowiecka-Rakus et al.103
  • -

    when administered three times, extension of survival was observed

  • -

    elevated NK cells and CD8+ cells and decreased CD4+ cells in the lung tissues

  • -

    elevated expression of immune-stimulatory genes in lung tissues